London-based uMotif raises £5m Series A
London-based uMotif – the patient-centric data capture software company has raised £5 million in a Series A investment round led by existing investor AlbionVC.
The funding, which also saw participation from Oslo-based DNV-GL and existing angel investors, will accelerate uMotif’s growth and will fuel further development of its patient-centric and decentralised approach to clinical studies and enable expansion into new study types and more high-demand territories.
Life sciences companies are increasingly embracing decentralised and virtual study designs – where patient consent and data is captured using their own devices from wherever they are located.
This is in stark contrast to the centralised, inconvenient and complex studies in which patients have to go to a site, such as a hospital, to submit their data. uMotif powers innovative decentralised and patient-centric approaches that increase how engaged patients are, thus improving the chances of the study’s success, reduce burden on participants, and help reach new patient populations to increase study diversity.
With studies taking place in 26 countries from clinical to real-world settings, and across more than 25 therapeutic areas – from dermatology and rare disease to oncology and cardiology, uMotif’s focus is to foster a highly engaging patient experience to capture larger volumes of higher quality data.
“We’re excited to help our customers implement patient-centred research designs by using the uMotif platform to capture high-quality data,” says Bruce Hellman, CEO and Co-Founder of uMotif.
“This new funding will rapidly accelerate our development and will ultimately help our customers to get new therapies to patients faster”.
Dr. Andrew Elder, Deputy Managing Partner at AlbionVC adds, “uMotif’s platform is built with patients in mind; designed to help academics, researchers and healthcare professionals to capture the best quality data in a way that suits the participants.
“It’s a win-win for all stakeholders and the platform has the potential and momentum to revolutionise the speed and efficiency with which therapies can reach and help millions of patients.”
Kaare Helle, Venture Director at DNV GL says: “Healthcare is dependent on digital transformation if it is to move towards being a more sustainable sector.
“We have been impressed with the platform and the management team at uMotif who are responsive to customer and patient needs and passionate about making a difference.”
The funding will further enhance uMotif’s highly configurable software platform to support existing studies and support new study designs, and will drive continued commercial growth and enable further geographical expansion.